Lumos Diagnostics Secures $2.98 million from BARDA for FebriDx Test Expansion

Proactive - Interviews for investors

Lumos Diagnostics Senior Vice President, Commercial Operations Paul Kase joined Steve Darling from Proactive to announce that the company has been awarded $2,984,571 by the Biomedical Advanced Research and Development Authority or BARDA. The funding will support a CLIA-waiver clinical study and regulatory submission for Lumos’ FebriDx® test, a diagnostic tool that differentiates between bacterial and non-bacterial acute respiratory infections. Kase highlighted that FebriDx® aims to reduce the over-prescription of antibiotics by offering clinicians quick and accurate evaluations. BARDA’s support will help expand the test’s utility from moderate/high complexity labs to CLIA-waived settings, such as physician offices, urgent care centers, and outpatient clinics. The funding strengthens Lumos’ efforts to provide better diagnostic tools in point-of-care environments, improving patient care and antibiotic stewardship. Kase also outlined the next steps, including the commencement of clinical trials later this month, which are crucial to securing full FDA approval for expanded use. He expressed excitement about Lumos’ mission to address antimicrobial resistance and how this grant accelerates their progress. #proactiveinvestors #lumosdiagnostics #asx #ldx #febridx #barda #BARDA #FebriDx #AntimicrobialResistance #FDAApproval #HealthcareInnovation #ClinicalTrials #MedicalDiagnostics #CLIAWaiver #AntibioticResistance#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews